Stock Events

Avidity Biosciences 

$48.15
40
+$3.43+7.67% Today

Statistics

Day High
48.27
Day Low
-
52W High
48.27
52W Low
4.83
Volume
1,003,902
Avg. Volume
1,618,787
Mkt Cap
4.6B
P/E Ratio
-16.27
Dividend Yield
-
Dividend
-

Earnings

9MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.93
-0.84
-0.75
-0.66
Expected EPS
-0.78
Actual EPS
-0.79

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RNA. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap13.76B
Sarepta Therapeutics focuses on the discovery and development of RNA-targeted therapeutics, particularly for rare neuromuscular diseases, directly competing with Avidity's focus on RNA-based therapies.
Ionis Pharmaceuticals
IONS
Mkt Cap6.98B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a direct competitor in the RNA therapy space.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.08B
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapies, targeting the same RNA-based therapeutic approach as Avidity.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap3.51B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, using RNAi technology similar to Avidity's approach.
Regulus Therapeutics
RGLS
Mkt Cap108.02M
Regulus Therapeutics is involved in the discovery and development of innovative medicines targeting microRNAs, a type of RNA, positioning it as a competitor in the RNA space.
Moderna
MRNA
Mkt Cap46.43B
Moderna is focused on drug discovery and drug development based on messenger RNA (mRNA), competing in the broader RNA therapeutics field.
BioNTech
BNTX
Mkt Cap20.32B
BioNTech SE works on individualized cancer medicine and other diseases using mRNA technology, making it a competitor in the RNA-based therapy market.
CRISPR Therapeutics
CRSP
Mkt Cap4.63B
CRISPR Therapeutics is engaged in the development of gene-based medicines, including RNA-targeted therapies, placing it in competition with Avidity.
Intellia Therapeutics
NTLA
Mkt Cap2.42B
Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, indirectly competing in the genetic and RNA therapy space.

Analyst Ratings

48.2$Average Price Target
The highest estimate is $60.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Show more...
CEO
Sarah Boyce
Employees
253
Country
US
ISIN
US05370A1088

Listings

XNAS
US
RNA